Aleksandra Glogowska

Aleksandra Glogowska

Auto-generated profile, based on publicly available information

Aleksandra Glogowska

Department of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2025 in Cancer Research
Verified
Journal Article
Closed access
DIDanyyl Ippolitov
Danyyl Ippolitov
YLYi-Han Lin
Yi-Han Lin
JSJeremy Spence
Jeremy Spence
AGAleksandra Glogowska
Aleksandra Glogowska
TTThatchawan Thanasupawat
Thatchawan Thanasupawat
SHSabine Hombach-Klonisch
Sabine Hombach-Klonisch
Brain metastasis occurs in about 50% of all women with metastatic HER2+ breast cancer and confers poor prognosis for patients. Despite effective HER2-targeted treatments of peripheral HER2+ breast cancer with trastuzumab and HER2 inhibitors, limited brain permeability renders these treatments inefficient for HER2+ breast cancer brain metastasis. The scarcity of suitable patient-derived in vivo models for HER2+ breast cancer brain metastasis has curtailed the study of molecular mechanisms that promote growth and therapeutic resistance in brain metastasis. In this study, we generated and characterized a luminal B HER2+ breast cancer brain metastasis cell model (BCBM94) isolated from a patient with HER2+ brain metastasis. Repeated hematogenic xenografting of BCBM94 consistently generated breast cancer brain metastasis in mice. The clinical receptor tyrosine kinase inhibitor (RTKi) lapatinib blocked phosphorylation of all ERBB receptors (ERBB1–4) and induced the intrinsic apoptosis pathway in BCBM94. Neuregulin 1 (Nrg1), an ERBB3/ERBB4 ligand that is abundantly expressed in the brain, abrogated lapatinib-induced apoptosis in HER2+ BCBM94 and BT474 models. ErbB3 signaling pathways that involved PI3K–AKT and the phosphorylation of BAD at serine 136 to prevent apoptosis were essential for Nrg1-induced survival. High-throughput RTKi screening identified the brain-penetrant pan-ErbB inhibitor poziotinib as a highly potent compound that reduced cell viability in HER2+ breast cancer brain metastasis in the presence of NRG1. Two weeks of poziotinib treatment successfully ablated BCBM94 and BT474 HER2+ brain tumors in vivo. In conclusion, this study established a patient-derived HER2+ breast cancer brain metastasis model and identified poziotinib as a highly efficacious RTKi with excellent brain penetrability that eliminated HER2+ breast cancer brain metastasis. Significance: Development of a preclinical patient-derived model to study HER2+ breast cancer brain metastasis enabled the identification of the irreversible pan-ERBB inhibitor poziotinib as highly efficacious in treating brain metastatic tumors.

17 June 2026
Verified
Other
Open access
DIDanyyl Ippolitov
Danyyl Ippolitov
YLYi-Han Lin
Yi-Han Lin
JSJeremy Spence
Jeremy Spence
AGAleksandra Glogowska
Aleksandra Glogowska
TTThatchawan Thanasupawat
Thatchawan Thanasupawat
SHSabine Hombach-Klonisch
Sabine Hombach-Klonisch
ErbB inhibitor response in the presence of rhNRG1

13 May 2025
Verified
Other
Open access
DIDanyyl Ippolitov
Danyyl Ippolitov
YLYi-Han Lin
Yi-Han Lin
JSJeremy Spence
Jeremy Spence
AGAleksandra Glogowska
Aleksandra Glogowska
TTThatchawan Thanasupawat
Thatchawan Thanasupawat
SHSabine Hombach-Klonisch
Sabine Hombach-Klonisch
Brain metastasis occurs in about 50% of all women with metastatic HER2+ breast cancer and confers poor prognosis for patients. Despite effective HER2-targeted treatments of peripheral HER2+ breast cancer with trastuzumab and HER2 inhibitors, limited brain permeability renders these treatments inefficient for HER2+ breast cancer brain metastasis. The scarcity of suitable patient-derived in vivo models for HER2+ breast cancer brain metastasis has curtailed the study of molecular mechanisms that promote growth and therapeutic resistance in brain metastasis. In this study, we generated and characterized a luminal B HER2+ breast cancer brain metastasis cell model (BCBM94) isolated from a patient with HER2+ brain metastasis. Repeated hematogenic xenografting of BCBM94 consistently generated breast cancer brain metastasis in mice. The clinical receptor tyrosine kinase inhibitor (RTKi) lapatinib blocked phosphorylation of all ERBB receptors (ERBB1–4) and induced the intrinsic apoptosis pathway in BCBM94. Neuregulin 1 (Nrg1), an ERBB3/ERBB4 ligand that is abundantly expressed in the brain, abrogated lapatinib-induced apoptosis in HER2+ BCBM94 and BT474 models. ErbB3 signaling pathways that involved PI3K–AKT and the phosphorylation of BAD at serine 136 to prevent apoptosis were essential for Nrg1-induced survival. High-throughput RTKi screening identified the brain-penetrant pan-ErbB inhibitor poziotinib as a highly potent compound that reduced cell viability in HER2+ breast cancer brain metastasis in the presence of NRG1. Two weeks of poziotinib treatment successfully ablated BCBM94 and BT474 HER2+ brain tumors in vivo. In conclusion, this study established a patient-derived HER2+ breast cancer brain metastasis model and identified poziotinib as a highly efficacious RTKi with excellent brain penetrability that eliminated HER2+ breast cancer brain metastasis.Significance: Development of a preclinical patient-derived model to study HER2+ breast cancer brain metastasis enabled the identification of the irreversible pan-ERBB inhibitor poziotinib as highly efficacious in treating brain metastatic tumors.

17 June 2026
Verified
Other
Open access
DIDanyyl Ippolitov
Danyyl Ippolitov
YLYi-Han Lin
Yi-Han Lin
JSJeremy Spence
Jeremy Spence
AGAleksandra Glogowska
Aleksandra Glogowska
TTThatchawan Thanasupawat
Thatchawan Thanasupawat
SHSabine Hombach-Klonisch
Sabine Hombach-Klonisch
Supplemental figures and legends

17 June 2026
Verified
Other
Open access
DIDanyyl Ippolitov
Danyyl Ippolitov
YLYi-Han Lin
Yi-Han Lin
JSJeremy Spence
Jeremy Spence
AGAleksandra Glogowska
Aleksandra Glogowska
TTThatchawan Thanasupawat
Thatchawan Thanasupawat
SHSabine Hombach-Klonisch
Sabine Hombach-Klonisch
Comparison ErbB inhibitor response in BCBM94 and NGN2 neurons

13 May 2025
Verified
Other
Open access
DIDanyyl Ippolitov
Danyyl Ippolitov
YLYi-Han Lin
Yi-Han Lin
JSJeremy Spence
Jeremy Spence
AGAleksandra Glogowska
Aleksandra Glogowska
TTThatchawan Thanasupawat
Thatchawan Thanasupawat
SHSabine Hombach-Klonisch
Sabine Hombach-Klonisch
ErbB inhibitor response in the presence of rhNRG1